Medicinova Stock Price, News & Analysis

MediciNova, Inc. (NASDAQ: MNOV) reported significant advancements in its drug development pipeline in its Q2 2021 update. The company initiated preclinical studies for MN-166 (ibudilast) targeting chlorine gas-induced lung disease, with positive Phase 2 results in alcohol use disorder published in Nature Journal, reinforcing MN-166's safety and potential. Ongoing patient enrollment continues for the Phase 3 trial of MN-166 in amyotrophic lateral sclerosis (ALS). Financially, MediciNova reported a cash balance of $77.8 million, projected to support operations through 2022.

MediciNova, trading on NASDAQ under the symbol MNOV, announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for treating ophthalmic diseases. This patent could extend protection until at least October 2039 and includes claims for treating macular injury. The drug is also in late-stage clinical trials for various neurodegenerative diseases, with encouraging results from previous studies. The patent may enhance MN-166's commercialization potential.

MediciNova, a biopharmaceutical company, announced that its leadership will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 4:30 pm ET. They will discuss their innovative clinical pipeline, including MN-166 (ibudilast), currently in Phase 3 trials for ALS and DCM. Additionally, MN-001 (tipelukast) is in Phase 2 trials for idiopathic pulmonary fibrosis. Investors can request one-on-one meetings via Ladenburg Thalmann.

MediciNova (NASDAQ: MNOV) has announced a mouse study to assess the efficacy of MN-166 (ibudilast) in treating chlorine-induced lung injuries. Conducted in partnership with BARDA, this study will evaluate survival rates and clinical outcomes following exposure to chlorine gas. MN-166 has shown potential in alleviating pulmonary damage and reducing inflammation in previous studies. MediciNova is leveraging federal funding for this project, which aligns with its broader development efforts for MN-166 in treating neurodegenerative diseases and acute respiratory conditions.

MediciNova, Inc. announced positive results from a Phase 2 trial of MN-166 (ibudilast) for treating alcohol use disorder (AUD) published in Nature’s Translational Psychiatry. The trial demonstrated a 45% reduction in heavy drinking odds and reduced alcohol craving on non-drinking days. The study involved 52 participants and aimed to assess mood and neural activation related to alcohol cues. These findings indicate potential for MN-166 as a novel AUD treatment, addressing the unmet medical need for effective therapies.

MediciNova, a biopharmaceutical company trading as MNOV, announced a fireside chat with CEO Yuichi Iwaki and VP Geoffrey O'Brien on June 23, 2021, at 1:00 pm ET, hosted by Maxim Group's Jason McCarthy. The company is focused on developing therapies for neurodegenerative, inflammatory, and fibrotic diseases, with MN-166 in Phase 3 trials for ALS and DCM. The drug is also in Phase 2 trials for glioblastoma and ARDS. MN-001 is in Phase 2 for idiopathic pulmonary fibrosis. MediciNova has 11 active clinical programs and is known for securing grants for its trials.

MediciNova has launched a sheep study to assess the efficacy of MN-166 (ibudilast) in treating chlorine-induced acute lung injury. In collaboration with BARDA, this study aims to evaluate pulmonary function and injury response. MN-166, already in late-stage development for neurological diseases, shows promise as a medical countermeasure for lung damage from chlorine exposure. The research could pave the way for innovative treatments without human trials under FDA's Animal Rule.

MediciNova completed a $20M private placement and formed a partnership with BARDA to develop MN-166 for acute lung injury from chlorine gas. The company received $4M in milestone payments from Genzyme and maintains a robust cash balance of $76M to support late-stage programs. Financial results for Q1 2021 include $4M in revenue and a net loss of just $0.2M, an improvement from the previous year. Key clinical trials are ongoing for MN-166 in ALS and COVID-19, alongside preparations for a Phase 2 study in NASH.

MediciNova, Inc. announced receiving a Notice of Intention to Grant from the European Patent Office for a patent covering the combination of MN-166 (ibudilast) and riluzole to treat amyotrophic lateral sclerosis (ALS). This patent is expected to expire no earlier than November 2035 and includes various dosing regimens. The company is currently conducting a Phase 3 clinical trial in the U.S. and Canada for this combination, which has received orphan-drug and fast-track designations from the FDA. MediciNova aims to enhance the treatment landscape for ALS, affecting approximately 16,000 patients in the U.S.